Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug cut seizure days in juvenile myoclonic epilepsy?

NCT ID NCT07723963

Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Sep 03, 2026 · Updated 3 times

Summary

This trial tests whether an experimental drug called JZP926 can safely reduce the number of days people aged 10 and older experience myoclonic seizures—brief, shock-like jerks—due to juvenile myoclonic epilepsy. Participants are randomly assigned to receive either JZP926 or a placebo twice daily. The study aims to see if the drug lowers seizure frequency and improves daily functioning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental drug called JZP926
What this could lead to
If it works, this could point toward a new treatment option for juvenile myoclonic epilepsy, potentially reducing seizure frequency.
What could go wrong
This is an early-to-mid-stage trial, so the drug may not prove effective or safe. Side effects are possible, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Participants are eligible to be included in the study only if all of the following criteria apply: 1. Is ≥ 10 years of age at the time of screening. 2. Has a diagnosis of JME per ILAE criteria as specified in the protocol. 3. Has at least 4 myoclonic seizure days per 28 days historical seizure frequency. Exclusion Criteria Participants are excluded from the study if any of the following criteria apply: 1. Presence of seizure types other than GTC, myoclonic, and absence seizures. 2. If historical MRI has been performed, participant's MRI reveals a cause of epilepsy other than JME. 3. Has a concurrent, confirmed diagnosis of non-epileptic seizures or events that can confound the assessment of the efficacy measures, in the opinion of the investigator. 4. The etiology of the participant's seizures is a progressive neurologic disease. 5. Has clinically unstable or progressive epilepsy. 6. Has clinically significant unstable medical condition(s), other than epilepsy, including unstable psychiatric disorders. 7. Has a history of status epilepticus in the 3 months prior to screening. 8. History of suicidal behavior, current suicidal risk as determined from history, or presence of active suicidal ideation as indicated by a positive response to Item 4 or Item 5 on the C-SSRS or is considered at risk of suicide or self-harm based on the clinical judgement of the investigator following interview with the participant and/or caregiver. 9. Has known or suspected hypersensitivity to cannabinoids or any of the excipients of the study intervention. 10. Is currently treated with Epidiolex or recently received treatment with Epidiolex within 28 days prior to screening. 11. Has a body weight \< 20 kg or \> 150 kg. 12. Is currently using or has used recreational or medicinal cannabis, cannabinoid/CBD based medications, products, or supplements (botanical or synthetic) within 28 days prior to screening. 13. Is unwilling or unable to abstain from recreational or medicinal cannabis, cannabinoid/CBD based medications, products, or supplements (botanical or synthetic) for the duration of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile myoclonic epilepsy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

juvenile myoclonic epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile myoclonic epilepsy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Banner University Medical Center

    Phoenix, Arizona, 85006, United States

  • Boston Children's Health Physicians

    Hawthorne, New York, 10532, United States

  • Carilion Clinic Neurology

    Roanoke, Virginia, 24016, United States

  • Cincinnati Children's Hospital

    Cincinnati, Ohio, 45229, United States

  • Consultants in Epilepsy and Neurology

    Boise, Idaho, 83702, United States

  • Corewell Health

    Grand Rapids, Michigan, 49503, United States

  • Emory Healthcare

    Atlanta, Georgia, 30329, United States

  • Hawaii Pacific Neuroscience, LLC

    Honolulu, Hawaii, 96817, United States

  • Louisiana State University

    Baton Rouge, Louisiana, 70803, United States

  • Northwell Health - Division of Pediatric Neurology

    Lake Success, New York, 11042, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Pediatric Epilepsy & Neurology Specialists

    Tampa, Florida, 33609, United States

  • Saint Peter's University Hospital

    New Brunswick, New Jersey, 08901, United States

  • Savannah Neurology Specialists

    Savannah, Georgia, 31406, United States

  • Sentara Neurology Specialists

    Virginia Beach, Virginia, 23456, United States

  • Sutter Health

    Dallas, Texas, 75219, United States

  • Weill Cornell Medicine - Pediatric Neurology

    New York, New York, 10021, United States

  • Winchester Neurological Consultants

    Winchester, Virginia, 22601, United States

  • Yale University

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.